Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows Developed in China, the combination therapy has potential to become a new, global standard of care

https://www.statnews.com/2026/05/21/merck-kelun-sac-tmt-lung-cancer-drug-trial-results/ By Adam FeuersteinMay 21, 2026 Senior Writer, Biotech